HK4597A - Nutritional, pharmaceutical and cosmetic compositions containing di-linoleoyl-mono-gamma-linolenyl-glycerol - Google Patents

Nutritional, pharmaceutical and cosmetic compositions containing di-linoleoyl-mono-gamma-linolenyl-glycerol

Info

Publication number
HK4597A
HK4597A HK4597A HK4597A HK4597A HK 4597 A HK4597 A HK 4597A HK 4597 A HK4597 A HK 4597A HK 4597 A HK4597 A HK 4597A HK 4597 A HK4597 A HK 4597A
Authority
HK
Hong Kong
Prior art keywords
gla
oil
dlmg
oil according
oils
Prior art date
Application number
HK4597A
Other languages
English (en)
French (fr)
Inventor
David F. Horrobin
Huang Yung-Sheng
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of HK4597A publication Critical patent/HK4597A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Edible Oils And Fats (AREA)
  • Detergent Compositions (AREA)
  • Logic Circuits (AREA)
  • Amplifiers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (9)

  1. Ein natürliches oder synthetisches Glyzeridöl, angereichert durch oder mit dem Zusatz von Dilinoleoyl-Mono-Gamma-Linolenyl-Glyzerol (DLMG), das mindestens 20 Massenanteile vorzugsweise mindestens 25 Massenanteile, noch besser mindestens 40 Massenanteile DLMG, enthält.
  2. Ein Öl nach Anspruch 1, das mindestens 60 Massenanteile, vorzugsweise mindestens 90 Massenanteile, noch besser mindestens 98 Massenanteile Triglyzerid enthält.
  3. Ein Öl nach Anspruch 1 oder 2, das ein nach pharmazeutischen oder Ernährungsgesichtspunkten akzeptables Öl ist.
  4. Verwendung eines Öls nach den Ansprüchen 1 bis 3, oder als Zusatz zu einem Nahrungsmittelzusatz oder als eine oder als Zusatz zu einer Nahrungsergänzung oder als eine oder als Zusatz zu besonderer Nahrung für Kleininder, ältere Kinder oder Erwachsene.
  5. Eine pharmazeutische Zusammensetzung, die ein Öl nach den Ansprüchen 1 bis 3 sowie einen pharmazeutische akzeptablen Träger enthält.
  6. Eine Zusammensetzung für Kosmetik oder Hautpflege, die aus einem Öl nach den Ansprüchen 1 bis 3 besteht, zur Verwendung bei der Behandlung von normaler, geschädigter oder kranker Haut.
  7. Die Verwendung eines Öls nach den Ansprüchen 1 bis 3 in einem Präparat zur Verwendung bei der Pflege oder Behandlung von normalem, geschädigtem oder kranken Haar oder Kopfhaut.
  8. Die Verwendung eines Öls nach den Ansprüchen 1 bis 3 in einem Präparat eines Arzneimittels zur Behandlung von GLS-Mangel.
  9. Die Verwendung eines Öls nach den Ansprüchen 1 bis 3 im Präparat eines Arzneimittels zur Behandlung einer Störung aus den Bereichen endogenes Ekzem, Brustschmerzen oder prämenstruelles Syndrom.
HK4597A 1991-06-03 1997-01-09 Nutritional, pharmaceutical and cosmetic compositions containing di-linoleoyl-mono-gamma-linolenyl-glycerol HK4597A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919111900A GB9111900D0 (en) 1991-06-03 1991-06-03 Fatty acid compositions

Publications (1)

Publication Number Publication Date
HK4597A true HK4597A (en) 1997-01-17

Family

ID=10695999

Family Applications (1)

Application Number Title Priority Date Filing Date
HK4597A HK4597A (en) 1991-06-03 1997-01-09 Nutritional, pharmaceutical and cosmetic compositions containing di-linoleoyl-mono-gamma-linolenyl-glycerol

Country Status (20)

Country Link
US (4) US5328691A (de)
EP (1) EP0520624B1 (de)
JP (1) JP2704922B2 (de)
KR (2) KR100274727B1 (de)
AT (1) ATE136214T1 (de)
AU (1) AU652827B2 (de)
CA (1) CA2069600C (de)
DE (1) DE69209571T2 (de)
DK (1) DK0520624T3 (de)
ES (1) ES2085567T3 (de)
FI (1) FI103867B (de)
GB (1) GB9111900D0 (de)
GR (1) GR3019840T3 (de)
HK (1) HK4597A (de)
IE (1) IE75224B1 (de)
NO (1) NO180804C (de)
NZ (1) NZ242898A (de)
SG (1) SG49739A1 (de)
TW (1) TW288975B (de)
ZA (1) ZA923913B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683027B2 (en) * 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
GB9304746D0 (en) * 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
FR2706304B1 (fr) * 1993-06-15 1995-09-01 Carita Sa Utilisation des huiles de Chaulmoogra dans le domaine cosmétique et pharmaceutique, notamment en dermatologie, pour harmoniser la pigmentation de la peau.
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
GB9403855D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
EP0707850A1 (de) * 1994-09-21 1996-04-24 Scotia Holdings Plc Verwendung von mehrfach ungesättigten Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von Brustschmerzen
EP0711503A3 (de) * 1994-11-14 1997-11-26 Scotia Holdings Plc Mit GLA und/oder DGLA angereicherte Milch
US5639460A (en) * 1995-06-07 1997-06-17 Raymond; Hal C. Aqueous plant extract having antiviral activity
US5959131A (en) * 1995-12-07 1999-09-28 Kraft Foods, Inc. Nutritionally superior fat for food compositions
WO1997036996A2 (en) * 1996-03-28 1997-10-09 Gist-Brocades B.V. Process for the preparation of a granular microbial biomass and isolation of valuable compounds therefrom
US6255505B1 (en) 1996-03-28 2001-07-03 Gist-Brocades, B.V. Microbial polyunsaturated fatty acid containing oil from pasteurised biomass
ATE328104T1 (de) * 1996-03-28 2006-06-15 Dsm Ip Assets Bv Mikrobielles polyungesättigte fettsäure enthaltendes öl und verfahren zur herstellung eines öls aus pasteurisierter und granulierter biomasse
IL133902A0 (en) 1997-07-16 2001-04-30 Impulse Dynamics Ltd Smooth muscle controller
US6107334A (en) * 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
GB9918023D0 (en) * 1999-07-30 1999-09-29 Unilever Plc Skin care composition
US6737084B2 (en) * 2000-06-27 2004-05-18 Qualilife Compositions and methods for enhancing or treating female sexual response
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
AU2003245978A1 (en) 2002-06-19 2004-01-06 Dsm Ip Assets B.V. Pasteurisation process for microbial cells and microbial oil
AU2003255863A1 (en) * 2002-07-31 2004-02-23 Helfried Hans Rudolf Crede Pharmaceutical composition containing black cumin oil, flax oil and borago oil
US7255972B2 (en) 2002-10-23 2007-08-14 Az Electronic Materials Usa Corp. Chemically amplified positive photosensitive resin composition
MXPA05008216A (es) * 2003-01-31 2005-10-05 Procter & Gamble Medios para mejorar la apariencia del tejido queratinoso mamifero.
US20050123500A1 (en) * 2003-01-31 2005-06-09 The Procter & Gamble Company Means for improving the appearance of mammalian hair and nails
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CN1856338B (zh) 2003-07-21 2012-11-14 超治疗有限公司 用于治疗疾病和控制血糖的胃肠方法和装置
FI20060154A7 (fi) 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
JP2006061021A (ja) * 2004-08-24 2006-03-09 Suntory Ltd １種類の高度不飽和脂肪酸残基３個から成るトリグリセライドの製造方法、およびその利用
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
JP2010042037A (ja) * 2009-11-26 2010-02-25 Suntory Holdings Ltd １種類の高度不飽和脂肪酸残基３個から成るトリグリセライドの製造方法、およびその利用
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
CN107666904B (zh) * 2015-03-26 2022-02-01 提贝托·布鲁泽塞 多不饱和脂肪酸的纯化组合物、其制备方法及其用途
MA47141A (fr) 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172149A (en) * 1978-01-30 1979-10-23 Westwood Pharmaceuticals, Inc. Method for treating living skin exhibiting excessive sebum secretion
DE2942021A1 (de) * 1979-10-17 1981-04-30 Bristol Myers Co Dermatologisches mittel
FR2490631A1 (fr) * 1980-09-24 1982-03-26 Roussel Uclaf Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique
US5145686A (en) * 1982-02-03 1992-09-08 Efamol Limited Topical pharmaceutical compositions
EP0092076B1 (de) * 1982-04-16 1986-12-17 Societe Des Produits Nestle S.A. Lipidhaltige Zusammensetzung für die orale, enterale oder parenterale Ernährung
US5011855A (en) * 1982-04-16 1991-04-30 Nestec S.A. Cosmetic and dermatological compositions containing γ-linolenic acid
IE54795B1 (en) * 1982-04-29 1990-02-14 Efamol Ltd Pharmaceutical composition
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
FR2569347B1 (fr) * 1984-08-22 1987-10-23 Mollet Marc Composition lipidique favorisant la pousse des phaneres et produits cosmetiques en renfermant
GB8516906D0 (en) * 1985-07-04 1985-08-07 Efamol Ltd Pharmaceutical & dietary composition
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
FR2588187B1 (fr) * 1985-10-07 1989-04-14 Rochas Parfums Nouvelles compositions cosmetiques ou dermatologiques riches en acides gras essentiels presents a la fois sous forme de triglycerides et sous forme libre ou salifiee
JPS6284041A (ja) * 1985-10-08 1987-04-17 Nitto Electric Ind Co Ltd γ−リノレン酸含有包接物
JPS62187425A (ja) * 1985-10-14 1987-08-15 Michio Nakanishi リノレン酸系化合物含有組成物
SE8604117D0 (sv) * 1986-09-29 1986-09-29 Kabivitrum Ab Composition
JPH0832628B2 (ja) * 1986-12-17 1996-03-29 株式会社ミドリ十字 トリグリセリド組成物
JPS6451496A (en) * 1987-08-21 1989-02-27 Nippon Oils & Fats Co Ltd Method of refining oil containing gamma-linolenic acid
FR2623692B1 (fr) * 1987-11-30 1991-05-03 Vernin Jean Gilles Nouvelle huile dietetique
GB8729153D0 (en) * 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
US5116871A (en) * 1988-09-13 1992-05-26 Efamol Holdings Plc Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy

Also Published As

Publication number Publication date
FI103867B1 (fi) 1999-10-15
FI922542L (fi) 1992-12-04
DE69209571D1 (de) 1996-05-09
NO922183D0 (no) 1992-06-02
DE69209571T2 (de) 1996-09-05
NZ242898A (en) 1994-12-22
KR100274727B1 (ko) 2000-12-15
NO180804B (no) 1997-03-24
DK0520624T3 (da) 1996-05-06
KR100277424B1 (ko) 2000-12-15
EP0520624A1 (de) 1992-12-30
JP2704922B2 (ja) 1998-01-26
SG49739A1 (en) 1998-06-15
NO922183L (no) 1992-12-04
CA2069600C (en) 2004-05-04
GR3019840T3 (en) 1996-08-31
AU1727892A (en) 1992-12-10
AU652827B2 (en) 1994-09-08
US5328691A (en) 1994-07-12
FI103867B (fi) 1999-10-15
IE921663A1 (en) 1992-12-16
ES2085567T3 (es) 1996-06-01
GB9111900D0 (en) 1991-07-24
NO180804C (no) 1997-07-02
ZA923913B (en) 1993-02-24
CA2069600A1 (en) 1992-12-04
IE75224B1 (en) 1997-08-27
EP0520624B1 (de) 1996-04-03
KR930000664A (ko) 1993-01-15
ATE136214T1 (de) 1996-04-15
TW288975B (de) 1996-10-21
US5552150A (en) 1996-09-03
JPH05201924A (ja) 1993-08-10
US5614208A (en) 1997-03-25
FI922542A0 (fi) 1992-06-02
US5620701A (en) 1997-04-15

Similar Documents

Publication Publication Date Title
EP0520624B1 (de) Nahrungs-, pharmazeutische und kosmetische Zubereitung, Dilinoleoyl-mono-gamma-linolenyl-glycerol enthaltend
US5670540A (en) Triglycerides of fatty acids
JP2003319759A (ja) 異性体濃縮共役リノール酸組成物の使用方法
CA2196880C (en) Nervonic acid compositions
EP0437520B1 (de) Triglyceride und nahrungszusammensetzung die diese enthält
WO2015050220A1 (ja) 油脂組成物
AU711302C (en) Nervonic acid compositions
CN106232113B (zh) 不饱和脂肪酸的吸收促进剂

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)